Massimo Bottini, Ph.D.

Massimo Bottini, Ph.D.

Increasing RA Drug Efficiency: A Clinical Project

Massimo Bottini, Ph.D.
Sanford-Burnham Medical Research Institute
La Jolla, California
Nanosystem for targeting Treg in vivo

Regulatory T cells (Treg) are an immune cell population that plays an active role in protecting humans against rheumatoid arthritis. The delivery of drugs specifically to Treg to boost their activity is highly desirable since it could lead to more efficient therapies against rheumatoid arthritis. However, there is still no approach to deliver drugs into specific immune cell populations in living animals.

Dr. Massimo Bottini has developed chemically engineered nanoscopic particles which can efficiently and safely bring pharmaceutical and diagnostic agents into selected cells in living animals. In this clinical study, he is targeting drug delivery only to Treg, and he predicts that new approaches and lower doses of drugs can be used, thereby opening new avenues for low-risk treatment and/or prevention of rheumatoid arthritis.

Article Author
Arthritis National Research Foundation

The Arthritis National Research Foundation's mission is to provide initial research funding to brilliant, investigative scientists with new ideas to cure arthritis and related autoimmune diseases. Writing articles about the patients affected and the science being done to find a cure shows why we need to come together to #CureArthritis!

No Comments

Sorry, the comment form is closed at this time.